GlaxoSmithKline has launched a multibillion pound restructuring drive, including a potential flotation of its HIV drugs business, in a push to win back shareholder support after a year marked by corruption allegations and faltering sales.
葛兰素史克（GlaxoSmithKline，简称GSK）发起巨额重组努力，包括可能让艾滋病(HIV)药物部门上市，试图在经历一年的腐败指控和疲弱销售后赢回股东的支持。
您已阅读10%（321字），剩余90%（2760字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。